JP2024522272A5 - - Google Patents
Info
- Publication number
- JP2024522272A5 JP2024522272A5 JP2023572540A JP2023572540A JP2024522272A5 JP 2024522272 A5 JP2024522272 A5 JP 2024522272A5 JP 2023572540 A JP2023572540 A JP 2023572540A JP 2023572540 A JP2023572540 A JP 2023572540A JP 2024522272 A5 JP2024522272 A5 JP 2024522272A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- seq
- oligonucleotide according
- lna
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202170290 | 2021-06-04 | ||
| DKPA202170290 | 2021-06-04 | ||
| PCT/EP2022/065217 WO2022254021A1 (en) | 2021-06-04 | 2022-06-03 | Antisense oligonucleotides targeting adenosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522272A JP2024522272A (ja) | 2024-06-13 |
| JP2024522272A5 true JP2024522272A5 (enExample) | 2025-07-07 |
Family
ID=82196319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572540A Pending JP2024522272A (ja) | 2021-06-04 | 2022-06-03 | アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240240188A1 (enExample) |
| EP (1) | EP4347824A1 (enExample) |
| JP (1) | JP2024522272A (enExample) |
| CN (1) | CN117642505A (enExample) |
| AU (1) | AU2022287241A1 (enExample) |
| WO (1) | WO2022254021A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4388096A1 (en) * | 2021-08-19 | 2024-06-26 | Neumirna Therapeutics ApS | Antisense oligonucleotides targeting adenosine kinase |
| WO2026068729A1 (en) * | 2024-09-26 | 2026-04-02 | Neumirna Therapeutics Aps | Antimir-27b for treatment of parkinson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| KR20020013513A (ko) | 1999-03-18 | 2002-02-20 | 추후제출 | Ｘｙｌｏ-ｌｎａ 유사체 |
| DE60029314T2 (de) | 1999-03-24 | 2007-07-12 | Exiqon A/S | Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside |
| AU7406700A (en) | 1999-10-04 | 2001-05-10 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| ATE287413T1 (de) | 2001-07-12 | 2005-02-15 | Santaris Pharma As | Verfahren zur herstellung des lna phosphoramidite |
| AU2003222743B2 (en) | 2002-05-08 | 2008-12-11 | Roche Innovation Center Copenhagen A/S | Synthesis of locked nucleic acid derivatives |
| US7481672B2 (en) | 2005-07-21 | 2009-01-27 | Rosemount Tank Radar Ab | Dielectric connector, DC-insulating through-connection and electronic system |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| EP2007888A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| EP2773779B1 (en) * | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| MX2016005855A (es) | 2013-11-14 | 2016-07-13 | Roche Innovation Ct Copenhagen As | Compuestos de conjugados antisentido de apolipoproteina b (apob). |
| TW202503057A (zh) | 2014-10-10 | 2025-01-16 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
-
2022
- 2022-06-03 WO PCT/EP2022/065217 patent/WO2022254021A1/en not_active Ceased
- 2022-06-03 AU AU2022287241A patent/AU2022287241A1/en active Pending
- 2022-06-03 EP EP22733330.9A patent/EP4347824A1/en active Pending
- 2022-06-03 JP JP2023572540A patent/JP2024522272A/ja active Pending
- 2022-06-03 CN CN202280039858.1A patent/CN117642505A/zh active Pending
- 2022-06-03 US US18/565,432 patent/US20240240188A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU704549B2 (en) | Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties | |
| US5591607A (en) | Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation | |
| US5726297A (en) | Oligodeoxyribonucleotide N3' P5' phosphoramidates | |
| FI4220360T3 (fi) | Oligonukleotideja paternaalisen ube3a:n ilmentämiseksi | |
| JP2005517427A5 (enExample) | ||
| JP2008283975A5 (enExample) | ||
| JP2018150344A5 (enExample) | ||
| JP2024522272A5 (enExample) | ||
| Liczner et al. | Beyond ribose and phosphate: selected nucleic acid modifications for structure–function investigations and therapeutic applications | |
| JP2005517438A5 (enExample) | ||
| FI3717646T3 (fi) | Angelmanin oireyhtymän antisense-hoito | |
| JP2021510511A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| JP2022527105A5 (enExample) | ||
| JP2023503635A (ja) | Ｒｎａ分子を合成する方法 | |
| JP2024516183A5 (enExample) | ||
| JP2024073525A5 (enExample) | ||
| JP2024536132A5 (enExample) | ||
| JP2024542738A5 (enExample) | ||
| TW202329983A (zh) | Ｒｎａ編輯 | |
| Nurmi et al. | A modified X10-23 DNAzyme that can better access large, structured RNA targets | |
| JP2023534720A5 (enExample) | ||
| JP2021513851A5 (enExample) | ||
| Wang et al. | Biophysical and biochemical properties of oligodeoxynucleotides containing 4′-C-and 5′-C-substituted thymidines | |
| JP2024547071A5 (enExample) |